PARIS--(BUSINESS WIRE)--

Regulatory News:

Exonhit (ALEHT.PA) announced today that it has been granted 1,928,000 by OSEO, as part of its involvement in a consortium led by ERYTECH Pharma and funded under the program for "Strategic Industrial Innovation". 1,126,000 were paid to Exonhit at the inception of the project during the first semester of 2012.

Headed by project leader ERYTECH Pharma, the consortium includes Exonhit, InGen BioSciences, AP-HP (Paris Public Hospitals), Inserm (National Institute for medical research), and Paris-Diderot University. It aims at developing innovative therapies for the enzymatic treatment of chemo- or radio-resistant cancers, and tools enabling personalized care of patients. This project, endorsed by the Competitiveness Cluster Lyonbiople, will last 8 years. The total amount awarded to the consortium amounts to approximately 10.7 million.

Exonhit was selected to participate in both phases of the project by using its proprietary Genome Wide SpliceArrayTM (GWSA) technology, to study tumor transcriptomic profiles in the initial phase, followed by the use of its capabilities in diagnostic test development to translate these profiles into a companion diagnostic.

The Company will be responsible for:

1) the identification of biomarkers of susceptibility to therapeutic response in the context of reducing the risks associated with the development of treatments, and

2) the development of an enzymatic therapy companion diagnostic that will identify responders, thus improving personalized care.

"This project is a new opportunity for the Company to implement its expertise in the development of companion diagnostics, and a key step in the implementation of our strategy in personalized medicine," said Loc Maurel, CEO of Exonhit. "The financial support of OSEO will also enable us to move towards solutions better adapted to the commercialization of diagnostics developed using our GWSA technology."

About the "Strategic Industrial Innovation" Program from OSEO

See original here:
Exonhit Receives € 1.93 Million from OSEO within the Personalized Medicine TEDAC Project in Cancer

Comments are closed.